Trial Profile
Use of Bevacizumab in the Treatment of Metastatic Colorectal Cancer (mCRC) in Italy: an Observational Cohort Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Antineoplastics
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms BEWARE
- Sponsors Roche
- 11 Mar 2019 Results published in the Tumori
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned end date changed from 1 Sep 2013 to 1 May 2013 as reported by ClinicalTrials.gov.